Praxis Precision Medicines (PRAX) Fireside Chat summary
Event summary combining transcript, slides, and related documents.
Fireside Chat summary
9 Jul, 2026Introduction and agenda
Special edition call convened to discuss recent developments and hot topics, including the re-rating that broadened investor interest.
Focus on Relutrigine and Ulixacaltamide, with updates on clinical progress and regulatory strategy.
Current industry trends
Accelerated regulatory pathways and Breakthrough Therapy Designation are shaping development timelines.
Increased investor and patient interest in rare epilepsy and essential tremor treatments.
Challenges and overcoming obstacles
Navigated regulatory uncertainty by maintaining close dialogue with the FDA and adapting study designs.
Addressed the need for robust efficacy data while balancing safety database requirements.
Overcame recruitment challenges by investing in data-driven site selection and patient identification.
Latest events from Praxis Precision Medicines
- Ulixacaltamide nears its PDUFA as commercial readiness and pipeline catalysts advance.PRAX
UBS Global Biopharma Conference 2026 - Two near-term launches anchor a pipeline with >$20B in peak-sales guidance.PRAX
Investor Day 2026 - Ulixacaltamide nears a January decision as launches and pipeline programs advance.PRAX
3rd Annual Guggenheim Healthcare Innovation Conference - Two NDAs near FDA decisions as $1.3B in liquidity supports operations into 2028.PRAX
Q3 2026 - $1.4B cash, late-stage FDA reviews, and commercial readiness drive 2027 launch plans.PRAX
Q2 2026 - Four CNS therapies with blockbuster potential target >$20B peak sales by 2028.PRAX
Corporate presentation - Pivotal epilepsy studies and a robust pipeline set up multiple clinical catalysts through early 2026.PRAX
Jefferies Global Healthcare Conference 2025 - Two NDAs filed, strong clinical data, and $1.5B cash position support 2026 launches.PRAX
Q4 2025 - Multiple late-stage clinical readouts and $433.8M cash support operations into 2027.PRAX
Q2 2024